Heparin cofactor II deficiency

Archives of Pathology and Laboratory Medicine

Volumn 126, Issue 11, 2002, Pages 1394-1400

  Tollefsen, Douglas M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN COFACTOR II;

CONFERENCE PAPER; DEEP VEIN THROMBOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; HEPARIN COFACTOR II DEFICIENCY; HUMAN; LABORATORY TEST; LUNG EMBOLISM; PRACTICE GUIDELINE; PROTEIN DEFICIENCY; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS;

ANIMALS; BLOOD COAGULATION TESTS; FAMILY HEALTH; FEMALE; HEPARIN COFACTOR II; HUMANS; MALE; MICE; MICE, KNOCKOUT; MUTATION; PRACTICE GUIDELINES; RISK FACTORS; THROMBOPHILIA; THROMBOSIS;

EID: 0036880595     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (101)

1. Tollefsen DM. Antithrombin deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001:4455-4471.
2. Sie P, Dupouy D, Pichon J, Boneu B. Turnover study of heparin cofactor II in healthy man. Thromb Haemost. 1985;54:635-638.
3. Shirk RA, Parthasarathy N, San Antonio JD, Church FC, Wagner WD. Altered dermatan sulfate structure and reduced heparin cofactor II-stimulating activity of biglycan and decorin from human atherosclerotic plaque. J Biol Chem. 2000; 275:18085-18092.
4. Liu L, Dewar L, Song Y, et al. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo. Thromb Haemost. 1995;73:405-412.
5. Andersson T, Lorentzen B, Hogdahl H, Clausen T, Mowinckel MC, Abildgaard U. Thrombin-inhibitor complexes in the blood during and after delivery. Thromb Res. 1996;82:109-117.
6. Massouh M, Jatoi A, Gordon EM, Ratnoff OD. Heparin cofactor II activity in plasma during pregnancy and oral contraceptive use. J Lab Clin Med. 1989; 114:697-699.
7. Bellart J, Gilabert R, Cabero L, Fontcuberta J, Monasterio J, Miralles RM. Heparin cofactor II: a new marker for pre-eclampsia. Blood Coagul Fibrinolysis. 1998;9:205-208.
8. Bellart J, Gilabert R, Fontcuberta J, Carreras E, Miralles RM, Cabero L. Coagulation and fibrinolytic parameters in normal pregnancy and in pregnancy complicated by intrauterine growth retardation. Am J Perinatol. 1998;15:81-85.
9. Andrew M, Mitchell L, Berry L, et al. An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus. J Clin Invest. 1992; 89:321-326.
10. He L, Vicente CP, Westrick RJ, Eitzman DT, Tollefsen DM. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest. 2002;109:213-219.
11. Ishiguro K, Kojima T, Kadomatsu K, et al. Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest. 2000;106:873-878.
12. Tollefsen DM, Pestka CA. Heparin cofactor II activity in patients with disseminated intravascular coagulation and hepatic failure. Blood. 1985;66:769-774.
13. Bertina RM, van der Linden IK, Engesser L, Muller HP, Brommer EJ. Hereditary heparin cofactor II deficiency and the risk of development of thrombosis. Thromb Haemost. 1987;57:196-200.
14. Toulon P, Costa JM, Amiral J. An enzyme-linked immunosorbent assay for heparin cofactor II (HCII): application to the measurement of HCII in clinical materials. Clin Chim Acta. 1992;205:65-73.
15. Rodeghiero F, Tosetto A. The VITA Project: population-based distributions of protein C, antithrombin III, heparin-cofactor II and plasminogen: relationship with physiological variables and establishment of reference ranges. Thromb Haemost. 1996;76:226-233.
16. Tosetto A, Ruggeri M, Castaman G, Rodeghiero F. Inherited abnormalities of blood coagulation in juvenile stroke: a case-control study. Blood Coagul Fibrinolysis. 1997;8:397-402.
17. Tosetto A, Gatto E, Rodeghiero F. Influence of cholesterol, triglycerides and fibrinogen on AT III, PC, HC-II and plasminogen measurement. Thromb Haemost. 1997;77:804.
18. Andersson TR, Larsen ML, Handeland GF, Abildgaard U. Heparin cofactor II activity in plasma: application of an automated assay method to the study of a normal adult population. Scand J Haematol. 1986;36:96-102.
19. Kario K, Matsuo T, Kobayashi H. Heparin cofactor II deficiency in the elderly: comparison with antithrombin III. Thromb Res. 1992;66:489-498.
20. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood. 1987;70:165-172.
21. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the healthy premature infant. Blood. 1988;72:1651-1657.
22. Chuansumrit A, Manco-Johnson MJ, Hathaway WE. Heparin cofactor II in adults and infants with thrombosis and DIC. Am J Hematol. 1989;31:109-113.
23. Manco-Johnson MJ, Abshire TC, Jacobson LJ, Marlar RA. Severe neonatal protein C deficiency: prevalence and thrombotic risk. J Pediatr. 1991;119:793-798.
24. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood. 1992;80:1998-2005.
25. Toulon P, Vitoux JF, Fiessinger JN, Sicard D, Aiach M. Heparin cofactor II: an acute phase reactant in patients with deep vein thrombosis. Blood Coagul Fibrinolysis. 1991;2:435-439.
26. Ezenagu LC, Brandt JT. Laboratory determination of heparin cofactor II. Arch Pathol Lab Med. 1986;110:1149-1151.
27. Toulon P, Vitoux JF, Capron L, Roncato M, Fiessinger JN, Aiach M. Heparin cofactor II in patients with deep venous thrombosis under heparin and oral anticoagulant therapy. Thromb Res. 1988;49:497-500.
28. Abildgaard U, Larsen ML. Assay of dermatan sulfate cofactor (heparin cofactor II) activity in human plasma. Thromb Res. 1984;35:257-266.
29. Tran TH, Duckert F. Heparin cofactor II determination: levels in normals and patients with hereditary antithrombin III deficiency and disseminated intravascular coagulation. Thromb Haemost. 1984;52:112-116.
30. Conard J, Bara L, Horellou MH, Samama MM. Bovine or human thrombin in amidolytic at III assays: influence of heparin cofactor II. Thromb Res. 1986;41: 873-878.
31. Mackie IJ, Segal H, Burren T, et al. Heparin cofactor II levels are increased by the use of combined oral contraceptives. Blood Coagul Fibrinolysis, 1990;1: 647-651.
32. Jobin F, Vu L, Lessard M. Two cases of inherited triple deficiency in a large kindred with thrombotic diathesis and deficiencies of antithrombin III, heparin cofactor II, protein C and protein S. Thromb Haemost. 1991;66:295-299.
33. Vinazzer H, Stocker K. Heparin cofactor II: experimental approach to a new assay and clinical results. Thromb Res. 1991;61:235-241.
34. Demers C, Henderson P, Blajchman MA, et al. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition. Thromb Haemost. 1993;69:231-235.
35. Tsakiris DA, Marbet GA, Makris PE, Settas L, Duckert F. Impaired fibrinolysis as an essential contribution to thrombosis in patients with lupus anticoagulant. Thromb Haemost. 1989;61:175-177.
36. Lo SC, Salem HH, Howard MA, Oldmeadow MJ, Firkin BG. Studies of natural anticoagulant proteins and anticardiolipin antibodies in patients with the lupus anticoagulant. Br J Haematol. 1990;76:380-386.
37. Keeling DM, Campbell SJ, Mackie IJ, Machin SJ, Isenberg DA. The fibrinolytic response to venous occlusion and the natural anticoagulants in patients with antiphospholipid antibodies both with and without systemic lupus erythematosus. Br J Haematol. 1991;77:354-359.
38. Muller B, Tsakiris DA, Roth CB, Guglielmetti M, Staub JJ, Marbet GA. Haemostatic profile in hypothyroidism as potential risk factor for vascular or thrombotic disease. Eur J Clin Invest. 2001;31:131-137.
39. Sie F, Meguira B, Bouissou F, Boneu B, Barthe P. Plasma levels of heparin cofactor II in nephrotic syndrome of children. Nephron. 1988;48:175-176.
40. Toulon P, Gandrille S, Remy P, Chadeuf G, Jouvin MH, Aiach M. Significance of high levels of heparin cofactor II in the plasma and urine of adult patients with nephrotic syndrome. Nephron. 1992;60:176-180.
41. Ruggeri M, Milan M, La Greca G, Castaman G, Rodeghiero F. Adult patients with the nephrotic syndrome: really at high risk for deep venous thromboembolism? Report of a series and review of the literature. Haematologica. 1993;78:47-51.
42. Hannedouche T, Fischer AM, Blanche P, Tapon-Bretaudiere J, Ganeval D. Plasma heparin cofactor II and antithrombin III concentrations in adult nephrotic syndrome. Clin Nephrol. 1987;28:305-306.
43. Vermylen CG, Levin M, Lanham JG, Hardisty RM, Barratt TM. Decreased sensitivity to heparin in vitro in steroid-responsive nephrotic syndrome. Kidney Int. 1987;31:1396-1401.
44. Grau E, Oliver A, Felez J, et al. Plasma and urinary heparin cofactor II levels in patients with nephrotic syndrome. Thromb Haemost. 1988;60:137-140.
45. Pech MA, Rostoker G, Soria C, et al. Heparin cofactor II in adult glomerulopathy and nephrotic syndrome. Am J Nephrol. 1991;11:74-75.
46. Sandset PM, Andersson TR. Coagulation inhibitor levels in pneumonia and stroke: changes due to consumption and acute phase reaction. J Intern Med. 1989;225:311-316.
47. Sandset PM, Hellgren M, Uvebrandt M, Bergstrom H. Extrinsic coagulation pathway inhibitor and heparin cofactor II during normal and hypertensive pregnancy. Thromb Res. 1989;55:665-670.
48. Toulon P, Bardin JM, Blumenfeld N. Increased heparin cofactor II levels in women taking oral contraceptives. Thromb Haemost. 1990;64:365-368.
49. Cortellaro M, Boschetti C, Crosignani PG. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study. The Writing Group for the Estradiol Clotting Factors Study. Thromb Haemost. 1996; 75:476-480.
50. Sie P, Dupouy D, Pichon J, Boneu B. Constitutional heparin co-factor II deficiency associated with recurrent thrombosis. Lancet. 1985;2:414-416.
51. Tran TH, Marbet GA, Duckert F. Association of hereditary heparin co-factor II deficiency with thrombosis. Lancet. 1985;2:413-414.
52. Andersson TR, Larsen ML, Abildgaard U. Low heparin cofactor II associated with abnormal crossed immunoelectrophoresis pattern in two Norwegian families. Thromb Res. 1987;47:243-248.
53. Simioni P, Lazzaro AR, Coser E, Salmistraro G, Girolami A. Hereditary heparin cofactor II deficiency and thrombosis: report of six patients belonging to two separate kindreds. Blood Coagul Fibrinolysis. 1990;1:351-356.
54. Jobin F, Vu L, Biogonesse JM. Follow-up: a young man with three deficiencies of antithrombotic proteins, asymptomatic until now, spontaneously develops pulmonary embolism. Thromb Haemost. 1992;67:730.
55. Weisdorf DJ, Edson JR. Recurrent venous thrombosis associated with inherited deficiency of heparin cofactor II. Br J Haematol. 1991;77:125-126.
56. Matsuo T, Kario K, Sakamoto S, et al. Hereditary heparin cofactor II deficiency and coronary artery disease. Thromb Res. 1992;65:495-505.
57. Simioni P, Zanardi S, Prandoni P, Girolami A. Combined inherited protein S and heparin co-factor II deficiency in a patient with upper limb thrombosis: a family study. Thromb Res. 1992;67:23-30.
58. Bernardi F, Legnani C, Micheletti F, et al. A heparin cofactor II mutation (HCII Rimini) combined with factor V Leiden or type I protein C deficiency in two unrelated thrombophilic subjects. Thromb Haemost, 1996;76:505-509.
59. Villa P, Aznar J, Vaya A, et al. Hereditary homozygous heparin cofactor II deficiency and the risk of developing venous thrombosis. Thromb Haemost. 1999; 82:1011-1014.
60. Kanagawa Y, Shigekiyo T, Aihara K, Akaike M, Azuma H, Matsumoto T. Molecular mechanism of type I congenital heparin cofactor (HC) II deficiency caused by a missense mutation at reactive P2 site: HC II Tokushima. Thromb Haemost. 2001;85:101-107.
61. Kondo S, Tokunaga F, Kario K, Matsuo T, Koide T. Molecular and cellular basis for type I heparin cofactor II deficiency (heparin cofactor II Awaji). Blood. 1996;87:1006-1012.
62. Corral J, Aznar J, Gonzalez-Conejero R, et al. Molecular characterization of the first homozygous heparin cofactor II deficiency: involvement in conformational disease [abstract]. Thromb Haemost. 2001;July suppl:OC987.
63. Blinder MA, Andersson TR, Abildgaard U, Tollefsen DM. Heparin cofactor IIOslo: mutation of Arg-189 to His decreases the affinity for dermatan sulfate. Biol Chem. 1989;264:5128-5133.
64. Malm J, Laurell M, Nilsson IM, Dahlback B. Thromboembolic disease: critical evaluation of laboratory investigation. Thromb Haemost. 1992;68:7-13.
65. Bick RL, Ucar K. Hypercoagulability and thrombosis. Hematol Oncol Clin North Am. 1992;6:1421-1431.
66. Awidi AS, Abu-Khalaf M, Herzallah U, et al. Hereditary thrombophilia among 217 consecutive patients with thromboembolic disease in Jordan. Am J Hematol. 1993;44:95-100.
67. Bandello F, Vigano D'Angelo S, Parlavecchia M, et al. Hypercoagulability and high lipoprotein(a) levels in patients with central retinal vein occlusion. Thromb Haemost. 1994;72:39-43.
68. Lopaciuk S, Bykowska K, Kopec M. Prevalence of heparin cofactor II deficiency in patients with a history of venous thrombosis. Pol J Pharmacol. 1996; 48:109-111.
69. Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism: results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost. 1997;77:444-451.
70. Vielhaber H, Ehrenforth S, Koch HG, Scharrer I, van der Werf N, Nowak-Gottl U. Cerebral venous sinus thrombosis in infancy and childhood: role of genetic and acquired risk factors of thrombophilia. Eur J Pediatr 1998;157:555-560.
71. Ehrenforth S, Junker R, Koch HG, et al. Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Childhood Thrombophilia Study Group. Eur J Pediatr. 1999;158:S97-S104.
72. Ho CH, Chau WK, Hsu HC, Gau JP, Yu TJ. Causes of venous thrombosis in fifty Chinese patients. Am J Hematol. 2000;63:74-78.
73. Andersson TR, Bell H. Plasma heparin cofactor II in alcoholic liver disease. J Hepatol. 1988;7:79-84.
74. Langley PG, Williams R. Physiological inhibitors of coagulation in fulminant hepatic failure. Blood Coagul Fibrinolysis. 1992;3:243-247.
75. Toulon P, Ledjev I, Ozier Y, Garnier JF, Houssin D. Lack of correction of acquired heparin cofactor II deficiency in patients with liver failure after successful orthotopic liver transplantation. Thromb Haemost. 1992;68:230-231.
76. Velasco F, Villalba R, Fernandez M, et al. Diminished anticoagulant and fibrinolytic activity following liver transplantation. Transplantation. 1992;53: 1256-1261.
77. Andersson TR, Sie P, Pelzer H, Aamodt LM, Nustad K, Abildgaard U. Elevated levels of thrombin-heparin cofactor II complex in plasma from patients with disseminated intravascular coagulation. Thromb Res. 1992;66:591-598.
78. Kario K, Matsuo T, Kodama K, Katayama S, Kobayashi H. Preferential consumption of heparin cofactor II in disseminated intravascular coagulation associated with acute promyelocytic leukemia. Thromb Res. 1992;66:435-444.
79. Toulon P, Jacquot C, Capron L, Frydman MO, Vignon D, Aiach M. Antithrombin III and heparin cofactor II in patients with chronic renal failure undergoing regular hemodialysis. Thromb Haemost. 1987;57:263-268.
80. Toulon P, Moulonguet-Doleris L, Costa JM, Aiach M. Heparin cofactor II deficiency in renal allograft recipients: no correlation with the development of thrombosis. Thromb Haemost. 1991;65:20-24.
81. Ceriello A, Quatraro A, Dello Russo P, Marchi E, Milani MR, Giugliano D. Evidence for a reduced heparin cofactor II biological activity in diabetes. Haemostasis. 1990;20:357-361.
82. Duboscq C, Quintana I, Barros J, Kordich L. Heparin cofactor II in diabetic patients. Blood Coagul Fibrinolysis. 1994;5:201-204.
83. Ceriello A, Marchi E, Barbanti M, et al. Non-enzymatic glycation reduces heparin cofactor II anti-thrombin activity. Diabetologia. 1990;33:205-207.
84. Mascia F, Paoletti P, Mameli G, Mamusa AM, Cirillo R, Marongiu F. Dermatan sulphate, heparin cofactor II, and F1 + 2 peptide in non-insulin-dependent diabetes mellitus. Thromb Res. 2000;97:263-265.
85. Meier P, Marbet GA, Berger W, Duckert F, Friedli W. Patterns of contact phase proteins indicating neuropathy in diabetic patients. Blut. 1990;61:222-225.
86. Gram J, Jespersen J. Increased concentrations of heparin cofactor II in diabetic patients, and possible effects on thrombin inhibition assay of antithrombin III. Clin Chem. 1989;35:52-55.
87. Porter JB, Young L, Mackie IJ, Marshall L, Machin SJ. Sickle cell disorders and chronic intravascular haemolysis are associated with low plasma heparin cofactor II. Br J Haematol. 1993;83:459-465.
88. O'Driscoll A, Mackie IJ, Porter JB, Machin SJ. Low plasma heparin cofactor II levels in thalassaemia syndromes are corrected by chronic blood transfusion. Br J Haematol. 1995;90:65-70.
89. Liesner R, Mackie I, Cookson J, et al. Prothrombotic changes in children with sickle cell disease: relationships to cerebrovascular disease and transfusion. Br J Haematol. 1998;103:1037-1044.
90. Toulon P, Chadeuf G, Bouillot JL, et al. Involvement of heparin cofactor II in chymotrypsin neutralization and in the pancreatic proteinase-antiproteinase interaction during acute pancreatitis in man. Eur J Clin Invest. 1991;21:303-309.
91. Boshkov LK, Warkentin TE, Hayward CP, Andrew M, Kelton JG. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol. 1993;84:322-328.
92. Street AM. Hunter's syndrome with an endogenous anticoagulant. Am J Hematol. 1996;53:277.
93. Andersen BS, Rahr HB, Sorensen JV. Determination of coagulation inhibitor levels and resistance to activated protein C in patients undergoing gastric surgery for benign and malignant disorders. Haemostasis. 1997;27:157-162.
94. Lindahl AK, Odegaard OR, Sandset PM, Harbitz TB. Coagulation inhibition and activation in pancreatic cancer: changes during progress of disease. Cancer. 1992;70:2067-2072.
95. Andersson TR, Berner NS, Larsen ML, Odegaard OR, Abildgaard U. Plasma heparin cofactor II, protein C and antithrombin in elective surgery. Acta Chir Scand. 1987;153:291-296.
96. Sandset PM, Hogevold HE, Lyberg T, Andersson TR, Abildgaard U. Extrinsic pathway inhibitor in elective surgery: a comparison with other coagulation inhibitors. Thromb Haemost. 1989;62:856-860.
97. Turner-Gomes SO, Mitchell L, Williams WG, Andrew M. Thrombin regulation in congenital heart disease after cardiopulmonary bypass operations. J Thorac Cardiovasc Surg. 1994;107:562-568.
98. Cardigan RA, Hamilton-Davies C, McDonald S, et al. Haemostatic changes in the pulmonary blood during cardiopulmonary bypass. Blood Coagul Fibrinolysis. 1996;7:567-577.
99. Chan AK, Leaker M, Burrows FA, et al. Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass. Thromb Haemost. 1997;77:270-277.
100. Toulon P, Lamine M, Ledjev I, et al. Heparin cofactor II deficiency in patients infected with the human immunodeficiency virus. Thromb Haemost. 1993;70:730-735.
101. Olson JD. College of American Pathologists Consensus Conference XXXVI: Diagnostic Issues in Thrombophilia: introduction and general considerations. Arch Pathol Lab Med. 2002;126:1277-1280.